Carolyn M. Klinge, Ph.D.

Professor

Department of Biochemistry and Molecular Biology


Baxter II Building, 580 S. Preston St. Room 221E 502-852-3668 502-852-3659 (fax) carolyn.klinge@louisville.edu

Education

B.A., 1979, Keuka College
M.S., 1981, The Pennsylvania University, The Milton S. Hershey College of Medicine
PhD, 1984, The Pennsylvania University, The Milton S. Hershey College of Medicine

Research Interests

Molecular Mechanisms of Estrogen Action

Mechanisms of Endocrine Resistance in Breast Cancer

Estrogens in Lung Adenocarcinoma

Transcriptional Regulation of Gene Expression Including miRNA Expression

Laboratory Personnel

Emberts, Celia
Radde, Brandie
Muluhngwi, Penn

Dr. Klinge’s research focuses on the molecular mechanisms by which estrogens regulate physiological functions in different cell types including breast and endometrial cancer, lung adenocarcinoma, and the vascular endothelium. The primary focus of the lab is to determine how estrogens regulate the expression of specific genes and microRNAs in a cell-type and promoter context-specific manner. Estrogens bind two different estrogen receptor proteins (ER) in the cell nucleus: ER? and ER?. In her main NIH-funded project, Dr. Klinge and members of her lab group are addressing how estrogens regulate nuclear-mitochondrial signaling by genomic and non-genomic mechanisms and the role of miRNAs in mediating estrogenic signaling in breast cancer cells. The goal of a second NIH-funded project is to determine the role of aberrant microRNA expression in endocrine- resistant breast cancer. Another project is addressing the role of COUP-TFII in antiestrogen-sensitivity and the mechanism for the decrease in COUP-TFII expression in endocrine-resistant breast cancer. A fourth project is supported by a grant from Joan’s Legacy and the Lungevity Foundations. In that work, Dr. Klinge and her group are examining the mechanisms accounting the gender disparity in lung adenocarcinoma and the role of coregulators and ER?-interacting proteins in this process. In a fifth project, supported by the American Heart Association, Dr. Klinge is examining how estradiol and the dietary chemical resveratrol, which is enriched in red wine, mediate cardioprotective effects in vascular endothelium. This project is examining intracellular mechanisms of estrogen action that are independent of nuclear ER activity. Two collaborative research projects are aimed at determining the anti-cancer activity of anacardic acid and the role of estrogen receptor signaling in thyroid cancer.

Selected Publications

Litchfield, L.M., Appana, S.N., Datta, S., and Klinge, C.M.  COUP-TFII inhibits NFκB activation in breast cancer cells and restores endocrine sensitivity. Mol. Cellular Endocrinol. 382: 358-367, 2014, PMID:24141032

Medjakovic, S., Zoechling, A., Gerster, P. Ivanova, M.M., Teng, Y., Klinge, C.M., Schildberger, B., Gartner, M., and Jungbauer, A.  Effect of non-persistent pesticides on estrogen receptor, androgen receptor, and aryl hydrocarbon receptor Environmental Toxicology, in press, 2013, ms.# TOX-12-189.  PMID:23436777

Manavalan, T.T., Teng, Y. Litchfield, L.M., Muluhngwi, P., Al-Rayyan, N., and Klinge, C.M.  Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells. PLoS ONE 8(4):e62334, 2013. PMID:23626803, PMCID:PMC3633860

Ivanova, M.M., Radde, B.N., and Klinge, C.M. Estradiol and tamoxifen regulate NRF-1 and mitochondrial function in mouse mammary gland and uterus. J. Mol.Endocrinol. 51: 233-246, 2013. NIHMSID #511126

Teng, Y., Manavalan, T.T., Hu, C., Medjakovic, S., Jungbauer, A., and Klinge, C.M.  Endocrine Disruptors Fludioxonil and Fenhexamid Stimulate miR-21 Expression in Breast Cancer Cells.  Toxicol. Sci. 131:71-83, 2013. Epub 2012 Oct 10, PMID:23052036

Jala, V.R., Radde, B.N., Haribabu, Bodduluri, and Klinge, C.M. Enhanced expression of G-protein coupled estrogen receptor (GPER/GPR30) in lung cancer.  BMC Cancer 12:624, 2013.PMID:23273253

Michael-Miller, K.K., Al-Numan, N., Mattingly, K.A., Ripp, S.L., Klinge, C.M., Prough, R.A. (both CMK and RAP are corresponding authors) DHEA metabolites activate estrogen receptors alpha and beta. Steroids 78: 15-25, 2013, Epub 2012 Nov 2, PMID:23123738  PMCID:PMC3529809; NIHMS 422148

Mattingly, K.A. and Klinge, C.M.  Diesel Exhaust Particle Extracts Inhibit Transcription of Nuclear Respiratory Factor-1 and Cell Viability in Human Umbilical Vein Endothelial Cells Archives of Toxicology 86: 633-42, 2012. PMID:22105178   PMCID:PMC3309133

Hsu, A., Zhang, W., Lee, J.F., An, J. Ekambaram, P, Liu, J., Honn, K.V., Klinge, C.M., and Lee, M-J.  Sphingosine-1-phosphate receptor-3 signaling up-regulates epidermal growth factor receptor and enhances epidermal growth factor receptor mediated carcinogenic activities in cultured lung adenocarcinoma cells. Int. J. Oncol. 40: 1619-26, 2012. PMID:22344462

Klinge CM. Inhibition of non-small-cell lung cancer growth by combined fulvestrant and vande Future Oncol. 2012 May;8(5):529-33, PMID:22646768

Klinge, C.M.  miRNAs and estrogen action.  Trends in Endocrinology and Metabolism 23: 223-33, 2012 PMID:22503553

Nweze, I.C., Smith, J.W., Zhang, B., Lakshmanan, J., Klinge, C.M., and Harbrecht, B.G.  17b-Estradiol attenuates cytokine-induced nitric oxide production in rat hepatocytes.  J. Trauma Acute Care Surg. 73: 408-12, 2012.  PMID:22846947

Litchfield, L.M., Riggs, K.A., Hockenberry, A.M., Oliver, L.D., Barnhart, K.G., Fox, J.M., Cai, J, Pierce, W.M.,Jr., Ivanova, M.M., Bates, P.J, Datta, S., Appana, S.N., Kulesza, P., McBryan, J., Young, L.S., and Klinge, C.M.  Nucleolin enhances COUP-TFII activation of retinoic acid receptor beta transcription in breast cancer cells. PLoS ONE 7 (5) e38278, 2012. Epub 2012 May 31, PMID:22693611   PMCID:PMC3365040

Litchfield, L.M. and Klinge, C.M. Multiple roles of COUP-TFII in cancer initiation and progression' J. Mol. Endocrinol.49: R135-148, 2012.  PMID:22966133  PMCID:PMC3469769

Manavalan TT, Teng Y, Appana SN, Datta S, Kalbfleisch TS, Li Y, Klinge CM. Differential expression of microRNA expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells. Cancer Lett. 2011 Dec 26;313(1):26-43. Epub 2011 Sep 10. PMID: 21955614

Ivanova M, Abner S, Pierce W Jr, Klinge C. Ligand-dependent differences in estrogen receptor beta-interacting proteins identified in lung adenocarcinoma cells corresponds to estrogenic responses. Proteome Sci. 2011 Sep 27;9(1):60. PMID: 21951318

Klinge CM, Radde BN, Imbert-Fernandez Y, Teng Y, Ivanova MM, Abner SM, Martin AL. Targeting the Intracellular MUC1 C-terminal Domain Inhibits Proliferation and Estrogen Receptor Transcriptional Activity in Lung Adenocarcinoma Cells. Mol Cancer Ther. 2011 Nov;10(11):2062-71. Epub 2011 Aug 23. PMID: 21862684

Imbert-Fernandez Y, Radde BN, Teng Y, Young WW Jr, Hu C, Klinge CM. MUC1/A and MUC1/B splice variants differentially regulate inflammatory cytokine expression. Exp Eye Res. 2011 Nov;93(5):649-57. Epub 2011 Aug 16. PMID: 21854773

Porter AM, Klinge CM, Gobin AS. Covalently grafted VEGF165 in hydrogel models upregulates the cellular pathways associated with angiogenesis. Am J Physiol Cell Physiol. 2011 Nov;301(5):C1086-92. Epub 2011 Jul 27. PMID: 21795519

Ivanova MM, Luken KH, Zimmer AS, Lenzo FL, Smith RJ, Arteel MW, Kollenberg TJ, Mattingly KA, Klinge CM. Tamoxifen increases nuclear respiratory factor 1 transcription by activating estrogen receptor beta and AP-1 recruitment to adjacent promoter binding sites. FASEB J. 2011 Apr;25(4):1402-16. Epub 2011 Jan 13. PMID: 21233487